18F-Fluciclovine for Brain Metastases Treatment
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Recruiting
Phase 1
Interventional Study
Brain Metastases, Adult
Brain Metastases
Brain Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 20 (estimated)
- Sponsor
- Baptist Health South Florida · Other
Who this trial is looking for
This trial is looking for adults with brain metastases who have at least one untreated lesion. Participants will help researchers see how well a new imaging agent works to track changes in their condition after radiation therapy.
Are You a Good Fit for This Trial?
You may be able to join if
- I am 18 years or older
- I have been diagnosed with brain metastases
- I have at least one untreated brain metastasis larger than 2 cm
- I will be receiving staged stereotactic radiosurgery
- If I am a woman who can become pregnant, I have a negative pregnancy test
- If I am a woman of reproductive potential, I am using effective contraception
You may not be able to join if
- I have had a severe allergic reaction to 18F-fluciclovine
- I have evidence of leptomeningeal disease
- I have had whole-brain radiation therapy before
- I cannot have an MRI for safety reasons
- I am pregnant or plan to be pregnant at the time of imaging
- I will be breastfeeding at the time of imaging and cannot stop for 24 hours
- I have a major medical illness or mental impairment that prevents completion of the study
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Male or female, age ≥18 years
2. Performance status, Eastern Cooperative Oncology Group 0-2
3. Confirmed diagnosis of brain metastases with at least one untreated lesion \>2 cm in maximum diameter
4. Plan for SSRS per the treating team
5. For women of childbearing potential, …
Contacts